While highly sensitive technology is important for detecting melanoma, methods with poor sensitivity can lead to unnecessary biopsies, treatments, cost, as well as morbidity. Several technologies are available to improve sensitivity and specificity, some of which are used as second-level tests.
New technologies for managing skin cancer were a topic of discussion at a scientific session at the American Society for Dermatologic Surgery’s 2015 annual meeting in Chicago in October. Seaver L. Soon, M.D., division of dermatology and dermatologic surgery at Scripps Clinic, La Jolla, Calif., was one of the moderators for the scientific discussion titled, “The Cutting Edge: New Technologies for Managing Skin Cancer.” Learn more
A new study suggests patients with darker skin types are more prone than those with lighter skin to acral pigmented lesions, and many people are unaware those lesions exist.
We’re looking back on what made the biggest impacts on dermatology in 2015. This is what your peers had to say.
Expert offers colleagues insight about the runner’s mentality on sunscreen and best practices for educating your local community
Transparent bioadhesive nanoparticles may offer alternative sun safety technology without the chemical exposure; questions remain
The ASDS, AAD, and other dermatology societies offer a wide variety of resources and programs that dermatologists can implement and get involved in to prevent skin cancer in their communities.
Survival rates for lentigo maligna (LM) melanoma-type melanomas vary. Acral lentiginous melanoma has a significantly worse survival rate than other melanoma subtypes with race appearing to play a role. Another factor may be poor awareness.
Lentigo maligna (LM) and acral lentiginous melanoma (ALM) can be challenging to diagnosis and treat, according to experts. Here, they offer insight into incidence, presentation, and management options. Learn more
It’s believed that viruses cause 15-20% of all cancer cases worldwide. New technologies have helped illuminate hundreds of new viruses and researchers are only beginning to understand how those resident in the skin may cause dermatologic disorders
In the treatment of non-melanoma skin cancer, “the fastest-moving area-and the neatest from a science standpoint-is the class of drugs called hedgehog pathway inhibitors.”
Clinicians agree that multi-disciplinary teams are the optimal approach to managing advanced melanoma, for they aim for consistent messaging to patients about treatment and require that physicians who are members of the team support their therapeutic choices with evidence. However, obstacles include geographical challenges in community care, treatment sequencing and bias, and physician communication.
Because skin malignancies often herald internal or systemic malignancies, knowing the link between primary and metastatic sites can impact staging, prognosis and management – and in some cases, save lives.
Immunosuppressed patient with recurrent squamous cell carcinoma succumbs to death. Was the dermatologist who did his skin evaluations negligent?
Researchers at Mayo Clinic’s Jacksonville, Fla., campus reported a discovery that could be the code for reprogramming cancer cells back to normal.
Due to the complexities and follow-up requirements of nonsurgical treatments for skin cancer, patient selection is critical. Expert offers tips for using various noninvasive treatment options for BCC, SCC, and melanoma.
Ongoing research is trying to identify strategies for overcoming resistance of advanced basal cell carcinoma to targeted therapy with a Hedgehog inhibitor. High level evidence to support adjuvant radiotherapy for high-risk non-melanoma skin cancers is lacking, but certain patients warrant evaluation by a multidisciplinary tumor board and treatment with adjuvant radiotherapy based on their risk for recurrence.
Advances in research have led to the emergence of medical therapies for BCCs; more research is needed to develop systemic therapies to treat SCCs.
Many patients and physicians have the misconception that the Hispanic population is not prone to skin cancer. As a result, these patients are not being diagnosed early.
Dr. Goldberg discusses five patient gifting situations. Are any of these acceptable?
Some patients respond more rapidly to immune therapies like ipilimumab, and clinicians have observed delayed toxicities with prolonged use of checkpoint inhibitors; effective treatments for subtypes of melanoma, such as uveal melanoma, have not yet emerged.
New and advancing forms of technology could improve the detection and treatment of melanoma.
Identifying specific neo-antigens in melanoma, a cancer known for having high numbers of genetic mutations caused by exposure to ultraviolet light, is no easy task. learn more.
Skin cancer prevention advocates can learn from the experiences of two skin cancer prevention programs aimed at identifying opportunities to educate young people about sun safety.
SLNB and GEP combined – powerful predictors of metastatic risk. Learn more on the studies results.
